Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 12,032.00
Ask: 12,036.00
Change: 98.00 (0.82%)
Spread: 4.00 (0.033%)
Open: 12,108.00
High: 12,142.00
Low: 11,994.00
Prev. Close: 11,930.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Henderson Group, AstraZeneca, IAG

Mon, 14th Sep 2015 16:39

(ShareCast News) - Exane BNP Paribas took a look at UK asset managers, noting that their shares have sold off sharply, making for an enticing entry point."Equity market volatility is a risk to inflows, but historically the impact has been temporary and flows into other asset classes do not suffer as much. Unless the market falls sharply, we think the outlook is strong."Exane initiated coverage of Henderson Group at 'outperform' with a 310 price target, saying it's the bank's top pick among the UK asset managers. It said the company has the best flow prospects and margin dynamics and is the most exposed to growth areas in asset management.It started Man Group at 'outperform' with a 190p price target, saying there's a high probability the company will make further acquisitions in the next 12-24 months. "Our analysis of previous deals shows that they have been value-accretive," it said.Coverage of Aberdeen Asset Management was initiated at 'underperform' with a 270p price target. It said Abederdeen has concentrated exposures to three flagship desks from which it expects further material outflows - global, global emerging markets and Asia Pacific equities - which together make up 60% of group revenues.Deutsche Bank upgraded AstraZeneca to 'buy' from 'hold' and raised its price target to 5,700p from 4,850p.The bank said it's increasingly confident in AstraZeneca's ability to deliver a return to strong growth from a base in 2017.Deutsche said while execution risks remain, the shares offer positive risk-reward and a level of upside optionality not available elsewhere in EU large-cap pharma sector.It noted that AZN's shares have underperformed EU pharma by more than 10% in 2015 and are trading at a discount to peers on a 2016 price-to-earnings ratio.Things were looking up for up for IAG shares in 2016 given improved pricing on its Transatlantic routes, the pricing behaviour within the sector in general and the stock's then current valuation, analysts at Credit Suisse said on Monday.The company's pricing in the third quarter "inspires confidence", making underlying growth of 49% in earnings before interest and taxes in the second half of 2015 "likely", analyst Neil Glynn said in a research note sent to clients.Glynn estimated the company's revenues would expand by 38% in 2016 if Aer Lingus was included and by 31% if not.Underpinning his argument, he pointed out how IAG's valuation relative to that of the top ten global airlines illustrated a 20% re-rating potential, suggesting the stock should trade at a lease-adjusted EV/IC ratio of 1.8 or six times EV/EBITDAR.On the back of the above the Swiss broker upped its target price on IAG stock by 14% to 852p from 750p while reiterating its 'outperform' recommendation.
More News
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.